Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 35Genitourinary 3Sarcoma 2CNS 2Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 410Lung Neoplasms 261Small Cell Lung Carcinoma 75Colorectal Neoplasms 71Breast Neoplasms 52Ovarian Neoplasms 48Neoplasms 48Melanoma 48Pancreatic Neoplasms 45Neoplasm Metastasis 38Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 31Prostatic Neoplasms 28Head and Neck Neoplasms 27Esophageal Neoplasms 26Carcinoma, Renal Cell 26Endometrial Neoplasms 25Colonic Neoplasms 24Triple Negative Breast Neoplasms 23Uterine Cervical Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Hepatocellular 21Mesothelioma, Malignant 14Mesothelioma 14Sarcoma 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Diseases 13Liver Neoplasms 13Carcinoma, Transitional Cell 13Thyroid Neoplasms 12

Interventions

spartalizumab 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Thoracic × 30 days × Clear all
NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
570 enrolled
Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡